Amneal Pharmaceuticals licenses ADL018 to Kashiv BioSciences

Kashiv BioSciences announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing Xolair, with Amneal Pharmaceuticals for the United States. Omalizumab, which targets free IgE, is a humanized monoclonal antibody. It is an injectable prescription drug used to treat a number of chronic conditions such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic spontaneous urticaria, and is typically administered in a hospital or clinic setting. The biosimilar was developed by Kashiv BioSciences, and is currently in a Phase III clinical trial, which began in the third quarter of 2023.